• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用比色β-内酰胺酶测定法对杜氏利什曼原虫临床分离株的无鞭毛体进行高通量药物筛选。

High-throughput screening of amastigotes of Leishmania donovani clinical isolates against drugs using a colorimetric beta-lactamase assay.

作者信息

Mandal Swati, Maharjan Mahendra, Ganguly Sudipto, Chatterjee Mitali, Singh Sarman, Buckner Frederick S, Madhubala Rentala

机构信息

School of Life Sciences, Jawaharlal Nehru University, New Delhi 110 067, India.

出版信息

Indian J Exp Biol. 2009 Jun;47(6):475-9.

PMID:19634714
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3127289/
Abstract

A simple colorimetric beta-lactamase assay for quantifying Leishmania amastigotes in macrophages grown in microtiter plates has been reported. The beta-lactamase gene was integrated into the rRNA region of the genome, thereby allowing for high-level stable expression of the enzyme. Both visceral leishmaniasis (VL) and post-kala azar dermal leishmaniasis (PKDL) isolates were transfected with beta-Lactamase gene. These beta-lactamase-expressing promastigotes were used for infecting intracellular J774A.1 macrophages in vitro. Quantification was done by a colorimetric readout with CENTA beta-lactamase as substrate and with an optical density plate reader. The assay was carried out in 96-well plates. Results obtained demonstrate that this methodology could be a valuable high-throughput screening assay for checking efficacy of anti-leishmanial drugs in the clinical isolates.

摘要

据报道,有一种简单的比色法β-内酰胺酶检测方法,可用于定量在微量滴定板中生长的巨噬细胞内的利什曼原虫无鞭毛体。β-内酰胺酶基因被整合到基因组的rRNA区域,从而使该酶能够高水平稳定表达。内脏利什曼病(VL)和黑热病后皮肤利什曼病(PKDL)的分离株均用β-内酰胺酶基因进行了转染。这些表达β-内酰胺酶的前鞭毛体用于体外感染细胞内的J774A.1巨噬细胞。通过以CENTAβ-内酰胺酶为底物并使用光密度酶标仪进行比色读数来进行定量。该检测在96孔板中进行。获得的结果表明,该方法可能是一种有价值的高通量筛选检测方法,可用于检查临床分离株中抗利什曼原虫药物的疗效。

相似文献

1
High-throughput screening of amastigotes of Leishmania donovani clinical isolates against drugs using a colorimetric beta-lactamase assay.使用比色β-内酰胺酶测定法对杜氏利什曼原虫临床分离株的无鞭毛体进行高通量药物筛选。
Indian J Exp Biol. 2009 Jun;47(6):475-9.
2
A parasite rescue and transformation assay for antileishmanial screening against intracellular Leishmania donovani amastigotes in THP1 human acute monocytic leukemia cell line.一种用于在THP1人急性单核细胞白血病细胞系中针对细胞内杜氏利什曼原虫无鞭毛体进行抗利什曼原虫筛选的寄生虫拯救与转化试验。
J Vis Exp. 2012 Dec 30(70):4054. doi: 10.3791/4054.
3
Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis.米替福新治疗内脏利什曼病和黑热病后皮肤利什曼病病例中利什曼原虫分离株的药物敏感性。
PLoS Negl Trop Dis. 2012;6(5):e1657. doi: 10.1371/journal.pntd.0001657. Epub 2012 May 22.
4
Antimony susceptible : evidence from drug susceptibility of parasites isolated from patients of post-kala-azar dermal leishmaniasis in pre- and post-miltefosine era.锑敏感:来自前米替福新时代和后米替福新时代间,从卡拉巴肿后皮肤利什曼病患者分离的寄生虫药物敏感性获得的证据。
Microbiol Spectr. 2024 Jun 4;12(6):e0402623. doi: 10.1128/spectrum.04026-23. Epub 2024 May 7.
5
Visceral and post-Kala-Azar dermal leishmaniasis isolates show significant difference in their in vitro drug susceptibility pattern.内脏利什曼病和卡拉·阿扎尔后皮肤利什曼病分离株的体外药物敏感性模式存在显著差异。
Parasitol Res. 2013 Mar;112(3):1001-9. doi: 10.1007/s00436-012-3222-1. Epub 2012 Dec 18.
6
Colorimetric assay for screening compounds against Leishmania amastigotes grown in macrophages.用于筛选针对巨噬细胞内生长的利什曼原虫无鞭毛体的化合物的比色测定法。
Am J Trop Med Hyg. 2005 May;72(5):600-5.
7
Post-kala-azar dermal leishmaniasis in visceral leishmaniasis-endemic communities in Bihar, India.印度比哈尔邦内脏利什曼病流行地区的黑热病后皮肤利什曼病。
Trop Med Int Health. 2012 Nov;17(11):1345-8. doi: 10.1111/j.1365-3156.2012.03067.x. Epub 2012 Aug 12.
8
Visceral leishmaniasis, or kala azar (KA): high incidence of refractoriness to antimony is contributed by anthroponotic transmission via post-KA dermal leishmaniasis.内脏利什曼病,即黑热病(KA):通过黑热病后皮肤利什曼病的人传人传播导致对锑难治性的高发生率。
J Infect Dis. 2006 Aug 1;194(3):302-6. doi: 10.1086/505079. Epub 2006 Jun 22.
9
Advanced case of PKDL due to delayed treatment: A rare case report.由于延迟治疗导致的晚期皮肤利什曼病:一例罕见病例报告。
PLoS Negl Trop Dis. 2020 Mar 23;14(3):e0008052. doi: 10.1371/journal.pntd.0008052. eCollection 2020 Mar.
10
Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh's National Kala-azar Elimination Programme.利用重点药物警戒确保孟加拉国国家黑热病消除规划中抗利什曼原虫药物的患者安全。
Infect Dis Poverty. 2018 Aug 13;7(1):80. doi: 10.1186/s40249-018-0461-0.

引用本文的文献

1
The Immune Memory Response of In Vitro-Polarised Th1, Th2, and Th17 Cells in the Face of Ovalbumin-Transgenic in a Mouse Model.在卵清蛋白转基因小鼠模型中,体外极化的 Th1、Th2 和 Th17 细胞对 Ovalbumin-Transgenic 的免疫记忆反应。
Int J Mol Sci. 2024 Aug 11;25(16):8753. doi: 10.3390/ijms25168753.
2
Induced pluripotent stem cell-derived human macrophages as an infection model for Leishmania donovani.诱导多能干细胞衍生的人源巨噬细胞作为感染利什曼原虫的模型。
PLoS Negl Trop Dis. 2024 Jan 2;18(1):e0011559. doi: 10.1371/journal.pntd.0011559. eCollection 2024 Jan.
3
Reporter gene systems: A powerful tool for studies.报告基因系统:研究的强大工具。
Curr Res Microb Sci. 2022 Sep 29;3:100165. doi: 10.1016/j.crmicr.2022.100165. eCollection 2022.
4
A Simple Bioluminescent Assay for the Screening of Cytotoxic Molecules Against the Intracellular Form of Leishmania infantum.一种用于筛选针对婴儿利什曼原虫细胞内形式的细胞毒性分子的简单生物发光测定法。
Methods Mol Biol. 2022;2524:127-147. doi: 10.1007/978-1-0716-2453-1_10.
5
Past and future of trypanosomatids high-throughput phenotypic screening.无。
Mem Inst Oswaldo Cruz. 2022 Mar 11;117:e210402. doi: 10.1590/0074-02760210402. eCollection 2022.
6
Challenges and Tools for In Vitro Exploratory Screening in the Drug Development Process: An Updated Review.药物研发过程中体外探索性筛选的挑战与工具:最新综述
Pathogens. 2021 Dec 10;10(12):1608. doi: 10.3390/pathogens10121608.
7
Potential of the natural products against leishmaniasis in Old World - a review of in-vitro studies.天然产物在旧世界利什曼病防治中的潜力——体外研究综述。
Pathog Glob Health. 2020 May 18;114(4):170-182. doi: 10.1080/20477724.2020.1754655. Epub 2020 Apr 27.
8
Evaluation of synergy between host and pathogen-directed therapies against intracellular Leishmania donovani.评估针对细胞内杜氏利什曼原虫的宿主和病原体导向治疗的协同作用。
Int J Parasitol Drugs Drug Resist. 2019 Aug;10:125-132. doi: 10.1016/j.ijpddr.2019.08.004. Epub 2019 Aug 21.
9
Antileishmanial Activity of Compounds Derived from the Medicines for Malaria Venture Open Access Box Against Intracellular Leishmania major Amastigotes.疟疾药物研发风险公开获取药盒中衍生化合物对细胞内硕大利什曼原虫无鞭毛体的抗利什曼活性
Am J Trop Med Hyg. 2016 Feb;94(2):340-347. doi: 10.4269/ajtmh.15-0448. Epub 2015 Oct 26.
10
A Review: The Current In Vivo Models for the Discovery and Utility of New Anti-leishmanial Drugs Targeting Cutaneous Leishmaniasis.综述:用于发现和应用针对皮肤利什曼病的新型抗利什曼原虫药物的当前体内模型
PLoS Negl Trop Dis. 2015 Sep 3;9(9):e0003889. doi: 10.1371/journal.pntd.0003889. eCollection 2015.

本文引用的文献

1
Impact of amphotericin-B in the treatment of kala-azar on the incidence of PKDL in Bihar, India.两性霉素B治疗黑热病对印度比哈尔邦皮肤利什曼病发病率的影响。
Indian J Med Res. 2008 Jul;128(1):38-44.
2
Role of ABC transporter MRPA, gamma-glutamylcysteine synthetase and ornithine decarboxylase in natural antimony-resistant isolates of Leishmania donovani.ABC转运蛋白MRPA、γ-谷氨酰半胱氨酸合成酶和鸟氨酸脱羧酶在杜氏利什曼原虫天然抗锑分离株中的作用
J Antimicrob Chemother. 2007 Feb;59(2):204-11. doi: 10.1093/jac/dkl494. Epub 2007 Jan 9.
3
Leishmania amastigotes as targets for drug screening.利什曼原虫无鞭毛体作为药物筛选的靶点。
Kinetoplastid Biol Dis. 2006 Oct 23;5:6. doi: 10.1186/1475-9292-5-6.
4
The genome of the kinetoplastid parasite, Leishmania major.动质体寄生虫硕大利什曼原虫的基因组。
Science. 2005 Jul 15;309(5733):436-42. doi: 10.1126/science.1112680.
5
Colorimetric assay for screening compounds against Leishmania amastigotes grown in macrophages.用于筛选针对巨噬细胞内生长的利什曼原虫无鞭毛体的化合物的比色测定法。
Am J Trop Med Hyg. 2005 May;72(5):600-5.
6
Post-kala-azar dermal leishmaniasis.黑热病后皮肤利什曼病
Lancet Infect Dis. 2003 Feb;3(2):87-98. doi: 10.1016/s1473-3099(03)00517-6.
7
Treatment of visceral leishmaniasis.内脏利什曼病的治疗。
Med Microbiol Immunol. 2001 Nov;190(1-2):89-92. doi: 10.1007/s004300100088.
8
The increase in risk factors for leishmaniasis worldwide.全球范围内利什曼病风险因素的增加。
Trans R Soc Trop Med Hyg. 2001 May-Jun;95(3):239-43. doi: 10.1016/s0035-9203(01)90223-8.
9
Treatment of visceral leishmaniasis with injectable paromomycin (aminosidine). An open-label randomized phase-II clinical study.注射用巴龙霉素(氨基糖苷)治疗内脏利什曼病:一项开放标签随机II期临床研究。
Trans R Soc Trop Med Hyg. 2000 Jul-Aug;94(4):432-3. doi: 10.1016/s0035-9203(00)90131-7.
10
Episomal and stable expression of the luciferase reporter gene for quantifying Leishmania spp. infections in macrophages and in animal models.用于定量巨噬细胞和动物模型中利什曼原虫感染的荧光素酶报告基因的游离型和稳定表达。
Mol Biochem Parasitol. 2000 Oct;110(2):195-206. doi: 10.1016/s0166-6851(00)00270-x.